Literature DB >> 11092612

Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides.

B W Anderson1, A P Kudelka, T Honda, M S Pollack, D M Gershenson, M A Gillogly, J L Murray, C G Ioannides.   

Abstract

Immunization with tumor antigens induces cellular and humoral immune responses. These responses by T cells are specific for defined epitopes (determinants) in the molecule of the immunizing tumor antigen. Extension of such responses to self-antigens requires induction of autoimmunity to the tumor. As with systems of autoimmune disease, expression of T cell autoimmunity is charaterized by diversification of responses from the inducer determinant to other responder (cryptic) determinants. Since similar strategies may be useful for therapy of human cancers, we investigated whether the induction of response to a HER-2 peptide F7 (776-789) induces enhanced reactivity of other HER-2 peptides. We found that stimulation with F7 can expand a response to another epitope F13 (884-899) in both an ovarian cancer patient with progressive disease and a healthy donor who shared HLA-DR11. This response was characterized mainly by increased interferon gamma secretion, and proliferation, but was not observed with another donor who shared HLA-DR14 and HLA-DQ5 with the patient. Since repeated vaccination with the same epitope may lead to a decline of primary cell reactivity caused by apoptosis spreading the response to other epitopes, the tumor antigen may provide an approach for maintaining an inflammatory Th1 response during cancer vaccination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092612     DOI: 10.1007/s002620000143

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

Authors:  Ana Lucia Dominguez; Joseph Lustgarten
Journal:  Vaccine       Date:  2009-11-18       Impact factor: 3.641

Review 2.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 3.  Antigen-specific active immunotherapy for ovarian cancer.

Authors:  Sterre T Paijens; Ninke Leffers; Toos Daemen; Wijnand Helfrich; H Marike Boezen; Ben J Cohlen; Cornelis Jm Melief; Marco de Bruyn; Hans W Nijman
Journal:  Cochrane Database Syst Rev       Date:  2018-09-10

4.  Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.

Authors:  R Sotiriadou; S A Perez; A D Gritzapis; P A Sotiropoulou; H Echner; S Heinzel; A Mamalaki; G Pawelec; W Voelter; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

Review 5.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

6.  Th1-Dominant CD4+ T Cells Orchestrate Endogenous Systematic Antitumor Immune Memory After Cryo-Thermal Therapy.

Authors:  Peng Peng; Yue Lou; Junjun Wang; Shicheng Wang; Ping Liu; Lisa X Xu
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.